ASCENTAGE PHARMA Trademark

Trademark Overview


On Friday, August 10, 2018, a trademark application was filed for ASCENTAGE PHARMA with the United States Patent and Trademark Office. The USPTO has given the ASCENTAGE PHARMA trademark a serial number of 79246610. The federal status of this trademark filing is REGISTERED as of Tuesday, October 8, 2019. This trademark is owned by JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.. The ASCENTAGE PHARMA trademark is filed in the Pharmaceutical Products category with the following description:

Medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations...
ascentage pharma

General Information


Serial Number79246610
Word MarkASCENTAGE PHARMA
Filing DateFriday, August 10, 2018
Status700 - REGISTERED
Status DateTuesday, October 8, 2019
Registration Number5876589
Registration DateTuesday, October 8, 2019
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 23, 2019

Trademark Statements


Goods and ServicesMedicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; antibiotics; pharmaceutical preparations in the form of injection for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for medical use; mineral food supplements; nutritional supplements
Disclaimer with Predetermined Text"PHARMA"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 30, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameJiangsu Ascentage Pharma Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCN

Party NameJIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCN

Party NameJIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCN

Trademark Events


Event DateEvent Description
Monday, April 1, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, April 1, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 1, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 1, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 1, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, April 1, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, March 27, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, December 25, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, March 13, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, February 3, 2020GENERIC MADRID TRANSACTION SENT TO IB
Monday, February 3, 2020GENERIC MADRID TRANSACTION CREATED
Wednesday, January 8, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 8, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, July 23, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2019PUBLISHED FOR OPPOSITION
Wednesday, July 3, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, June 14, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 13, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 12, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 12, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 11, 2019REFUSAL PROCESSED BY IB
Friday, December 21, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, December 20, 2018REFUSAL PROCESSED BY MPU
Tuesday, December 11, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, December 10, 2018NON-FINAL ACTION WRITTEN
Tuesday, December 4, 2018APPLICATION FILING RECEIPT MAILED
Friday, November 30, 2018ASSIGNED TO EXAMINER
Friday, November 30, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 29, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB